Lupus Patient Says 'I've Never Been This Good' After Revolutionary Immune Reset
- 5 out of 6 patients remain in remission after immune reset treatment
- One patient showed improvement but had a flare after 11 months
- Experimental treatment resets the immune system
- Lupus is a chronic autoimmune disease
- Current treatments often control symptoms but rarely achieve lasting remission
An experimental treatment that resets a malfunctioning immune system has put the disease lupus into remission in early UK trials.
Officials said the treatment has shown promising results, with 5 out of 6 patients remaining in remission.
The long-term effectiveness and broader applicability of the treatment remain uncertain.
- 5 out of 6 patients remain in remission.
- One patient showed improvement but had a flare after 11 months.
How The Immune Reset Treatment Works
The treatment involves removing a type of white blood cell, called T lymphocytes, and engineering them to spot and destroy disease.
Sources confirmed that the T-cells are then fed back into the patient via an infusion to reset their immune system.
Experts said the therapy is already revolutionising cancer treatment.
Witnesses said the treatment has the potential to offer people a cure for lupus.
Impact On Patients
One patient said 'I've never been this good' after receiving the treatment.
Government sources said the treatment has shown significant promise in putting lupus into remission.
However, officials also said that more research is needed to determine the long-term effectiveness of the treatment.
Meanwhile, patients who have received the treatment are hopeful that it will lead to a cure for the disease.
Context Of The Disease
Lupus is a chronic autoimmune disease in which the immune system attacks the body's own tissues, causing widespread inflammation and organ damage.
Current treatments often control symptoms but rarely achieve lasting, drug-free remission.
Historically, lupus has been a difficult disease to treat, with many patients experiencing persistent, treatment-resistant disease.
Despite this, recent clinical studies suggest that a novel therapy using CD19 chimeric antigen receptor (CAR) T cells can induce profound and long-lasting remission in patients with severe, refractory lupus.
Human Impact Of The Treatment
The treatment has the potential to significantly improve the lives of people with lupus.
Patients who have received the treatment are hopeful that it will lead to a cure for the disease.
However, officials also said that more research is needed to determine the long-term effectiveness of the treatment.
In contrast, the treatment has already shown significant promise in putting lupus into remission, giving patients new hope for a cure.
Despite the uncertainty surrounding the treatment, patients and doctors are optimistic about its potential to revolutionise the treatment of lupus.